Kezar Life Sciences (KZR) Competitors $3.95 -0.02 (-0.48%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR vs. ZNTL, CNTB, ZURA, CRBP, CGTX, SAVA, CRDL, SKYE, SPRO, and ONCYShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Zentalis Pharmaceuticals (ZNTL), Connect Biopharma (CNTB), Zura Bio (ZURA), Corbus Pharmaceuticals (CRBP), Cognition Therapeutics (CGTX), Cassava Sciences (SAVA), Cardiol Therapeutics (CRDL), Skye Bioscience (SKYE), Spero Therapeutics (SPRO), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. Its Competitors Zentalis Pharmaceuticals Connect Biopharma Zura Bio Corbus Pharmaceuticals Cognition Therapeutics Cassava Sciences Cardiol Therapeutics Skye Bioscience Spero Therapeutics Oncolytics Biotech Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Is ZNTL or KZR more profitable? Zentalis Pharmaceuticals' return on equity of -51.62% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -51.62% -40.28% Kezar Life Sciences N/A -63.51%-52.13% Which has more risk and volatility, ZNTL or KZR? Zentalis Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Which has preferable earnings and valuation, ZNTL or KZR? Kezar Life Sciences has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$67.43M1.81-$165.84M-$2.26-0.75Kezar Life Sciences$7M4.13-$83.74M-$9.69-0.41 Does the media refer more to ZNTL or KZR? In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Kezar Life Sciences. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 2 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 0.94 beat Zentalis Pharmaceuticals' score of 0.54 indicating that Kezar Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kezar Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ZNTL or KZR? 67.9% of Kezar Life Sciences shares are owned by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer ZNTL or KZR? Zentalis Pharmaceuticals currently has a consensus price target of $8.20, suggesting a potential upside of 385.21%. Kezar Life Sciences has a consensus price target of $9.00, suggesting a potential upside of 127.85%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Zentalis Pharmaceuticals is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryZentalis Pharmaceuticals beats Kezar Life Sciences on 10 of the 16 factors compared between the two stocks. Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.07M$3.08B$5.69B$9.86BDividend YieldN/A2.29%3.99%4.02%P/E Ratio-0.4120.7879.6626.58Price / Sales4.13392.01536.52112.00Price / CashN/A44.0537.7059.65Price / Book0.328.0710.576.59Net Income-$83.74M-$53.98M$3.27B$265.83M7 Day Performance-2.71%-0.88%0.61%0.18%1 Month Performance-8.78%5.67%5.43%2.13%1 Year Performance-33.95%9.07%50.37%21.07% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences3.8423 of 5 stars$3.95-0.5%$9.00+127.8%-35.4%$29.07M$7M-0.4160News CoverageZNTLZentalis Pharmaceuticals1.9163 of 5 stars$1.64+3.1%$8.20+400.0%-42.5%$114.69M$67.43M-0.73160CNTBConnect Biopharma3.2922 of 5 stars$1.92-6.3%$7.00+264.6%+72.5%$114.23M$26.03M0.00110Upcoming EarningsZURAZura Bio3.0086 of 5 stars$1.74+4.8%$14.17+714.2%-49.8%$113.50MN/A-2.493CRBPCorbus Pharmaceuticals4.4055 of 5 stars$9.25flat$49.00+429.7%-82.3%$113.36MN/A-1.9440News CoveragePositive NewsCGTXCognition Therapeutics2.4052 of 5 stars$1.49-3.2%$2.83+90.2%+262.0%$113.15MN/A-2.2220Gap UpSAVACassava Sciences1.7009 of 5 stars$2.27-3.0%$2.00-11.9%-91.1%$113.04MN/A-0.8930CRDLCardiol Therapeutics2.4278 of 5 stars$1.22-6.9%$8.00+555.7%-43.2%$109.66MN/A-3.5920Positive NewsGap UpSKYESkye Bioscience1.5988 of 5 stars$3.39-3.4%$15.50+357.2%-42.7%$108.77MN/A-3.2011SPROSpero Therapeutics4.0369 of 5 stars$1.91flat$5.00+161.8%+46.0%$107.49M$47.98M-1.95150Positive NewsONCYOncolytics Biotech1.7586 of 5 stars$1.01-6.5%$5.00+395.0%+11.5%$105.20MN/A-3.7430 Related Companies and Tools Related Companies ZNTL Competitors CNTB Competitors ZURA Competitors CRBP Competitors CGTX Competitors SAVA Competitors CRDL Competitors SKYE Competitors SPRO Competitors ONCY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZR) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access